Harry P. Erba, MD, PhD prepared useful practice aids pertaining to acute myeloid leukemia for this CME/MOC activity titled "Advances in AML Care: Highlights From Recent Science." For the full presentation, monograph, complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/2Xsu5x1. CME/MOC credit will be available until June 15, 2021.

1. Access the activity,“Advances in AML Care: Highlights From Recent Science,”at PeerView.com/VKE40
A Snapshot of Innovative Therapies in AML
Current Status, Dosing, and Other Considerations
PRACTICE AID
STATUS DOSEDRUG CONSIDERATIONSTARGET
Approved
Plus chemotherapy in adults with newly
diagnosed FLT3-mutation–positive AML
50 mg orally twice daily with food on
d 8-21 of each induction cycle with
cytarabine and daunorubicin and on
d 8-21 of each consolidation cycle with
high-dose cytarabine
Midostaurin4
q GI events most common
q Promote therapy adherence
q Be mindful of potential drug–drug interactions
FLT3
Approved
Adults with R/R
IDH2-mutation–positive AML
100 mg orally daily
Enasidenib10
Monitor for:
q IDH-differentiation syndrome
q GI events
IDH2 q Elevated bilirubin
q Leukocytosis
Approved
Adults with IDH1-mutation–positive newly
diagnosed AML who are ≥75 years or
who have comorbidities that preclude
the use of intensive induction
chemotherapy or R/R AML
500 mg orally daily
Ivosidenib11
Monitor for:
q IDH-differentiation syndrome
q Guillain-Barré syndrome
IDH1 q QT prolongation
q GI events, nausea,
leukocytosis
Phase 3 testing
Adults with newly diagnosed and R/R
FLT3-ITD–positive AML
60 mg used in phase 3 QuANTUM-R
study (30-mg lead-in)Quizartinib6-9
q Most common AEs in early studies included nausea,
prolonged QT interval, vomiting, and dysgeusia
FLT3
Approved
Adults with newly diagnosed
t-AML or AML-MRC
Induction: daunorubicin 44 mg/m2
and
cytarabine 100 mg/m2
liposome IV
over 90 min on d 1, 3, and 5a
CPX-3511-3
q Can cause prolongation of blood count suppression;
monitor blood counts regularly until recovery
q Not recommended in patients with decreased cardiac
function
Cytotoxic therapy
(liposomal cytarabine
+ daunorubicin
5:1 molar ratio)
Approved
Adults with FLT3-mutation–positive
R/R AML
120 mg orally daily
Gilteritinib5
q Most common AEs include myalgia/arthralgia,
transaminase increase, fatigue/malaise, noninfectious
diarrhea, dyspnea, edema, rash, pneumonia, nausea,
stomatitis, cough, headache, hypotension, dizziness,
and vomiting
FLT3
Approved
In combination with azacitidine or
decitabine or low-dose cytarabine for
newly diagnosed AML in adults
≥75 years or who have comorbidities
that preclude use of intensive
induction chemotherapy
BCL-2
Ramp-up phase: 100 mg orally on d 1,
200 mg on d 2, 400 mg on d 3;
d 4 and beyond: 400 mg (with HMA)
or 600 mg (with low-dose cytarabine)
q Most common AEs as part of combination therapy in
AML include nausea, diarrhea, thrombocytopenia,
constipation, neutropenia, febrile neutropenia, and
fatigue (among others)b
q Standard monitoring and prophylaxis measures for TLS
are recommended
Venetoclax12

2. a
For additional induction, use d 1 and 3 for subsequent cycles, if needed; for consolidation: daunorubicin 29 mg/m2
and cytarabine 65 mg/m2
liposome IV over 90 min on d 1 and 3. b
See prescribing information for a complete list of common AEs with venetoclax combinations in AML.12
AML: acute myeloid leukemia; AML-MRC: AML with myelodysplasia-related changes; BCL-2: B cell lymphoma 2; BM: bone marrow; CD: cluster of differentiation; FLT3: fms-like tyrosine kinase 3; FN: febrile neutropenia; HCT: hematopoietic cell transplantation; Hhp: hedgehog pathway; HMA: hypomethylating agent;
IDH: isocitrate dehydrogenase; ITD: internal tandem duplication; mAb: monoclonal antibody; RFS: relapse-free survival; R/R: relapsed or refractory; t-AML: therapy-related acute myeloid leukemia; TLS: tumor lysis syndrome; VOD: veno-occlusive disease.
1. Lancet JE et al. 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO 2016). Abstract 7000. 2. Lancet JE et al. 2017 Annual BMT Tandem Meetings (BMT Tandem 2017). Abstract 19. 3. Vyxeos (daunorubicin and cytarabine) Prescribing Information. http://pp.jazzpharma.com/pi/
vyxeos.en.USPI.pdf. 4. Rydapt (midostaurin) Prescribing Information. https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/rydapt.pdf. 5. Xospata (gilteritinib) Prescribing Information. https://astellas.us/docs/xospata.pdf. 6. https://clinicaltrials.gov/ct2/show/NCT02668653.
7. https://clinicaltrials.gov/ct2/show/NCT02039726. 8. Cortez J et al. 23rd Congress of the European Hematology Association (EHA 2018). Abstract LB2600. 9. https://pharmaphorum.com/market-access-2/fda-grants-leukaemia-drug-breakthrough-status/. 10. Idhifa (enasidenib) Prescribing Information.
https://media.celgene.com/content/uploads/idhifa-pi.pdf. 11. Tibsovo (ivosidenib) Prescribing Information. https://www.tibsovo.com/pdf/prescribinginformation.pdf. 12. Venclexta (venetoclax) Prescribing Information. https://www.rxabbvie.com/pdf/venclexta.pdf. 13. Mylotarg (gemtuzumab
ozogamicin) Prescribing Information. http://labeling.pfizer.com/ShowLabeling.aspx?id=9548. 14. https://www.fda.gov/drugs/fda-approves-glasdegib-aml-adults-age-75-or-older-or-who-have-comorbidities . 15. Daurismo (glasdegib) Prescribing Information. http://labeling.pfizer.com/ShowLabeling.
aspx?id=11336. 16. Agura E et al. 60th American Society of Hematology Annual Meeting and Exposition (ASH 2018). Abstract 1017. 17. Roboz GJ et al. FutureOncol. 2016;12:293-302. 18. Wei AH et al. 61st Annual Meeting and Exposition of the American Society of Hematology (ASH 2019). Abstract LBA-3.
Access the activity,“Advances in AML Care: Highlights From Recent Science,”at PeerView.com/VKE40
A Snapshot of Innovative Therapies in AML
Current Status, Dosing, and Other Considerations
PRACTICE AID
DRUG STATUS TARGET DOSE CONSIDERATIONS
Glasdegib14,15
Approved
In combination with low-dose cytarabine
for newly diagnosed AML in adults
≥75 years or who have comorbidities
that preclude use of intensive
induction chemotherapy
Hhp 100 mg orally daily
q Most common AEs include anemia, fatigue,
hemorrhage, FN, musculoskeletal pain, nausea,
edema, thrombocytopenia, and dyspnea
q See label for other common AEs and for information
on the potential for embryo-fetal toxicity and appropriate
management approaches
Gemtuzumab
ozogamicin13
Approved
Newly diagnosed CD33+ AML in adults,
R/R CD33+ AML in adults, and in
pediatric patients aged ≥2 years
CD33
Induction: 3 mg/m2
(up to one
4.5-mg vial) on d 1, 4, and 7 in
combination with daunorubicin
and cytarabine
q Infusion-related reactions
q Premedicate with corticosteroid, antihistamine,
and acetaminophen
q Monitor platelet counts frequently (hemorrhage) and
signs/symptoms of liver toxicity (VOD)
Phase 3 SIERRA study
Adults aged ≥55 years with active,
R/R AML, adequate organ function,
and related/unrelated matched donor
CD45
(BC8 mAb
linked to
radioisotope
iodine-131)
Dosimetry directed
(SIERRA study)
Iomab-B16
Phase 2 data as maintenance therapy
post-HCT in AML
Phase 3 QUAZAR study
Maintenance with oral azacitidine in
adults aged ≥55 years with AML in
first complete remission induced
substantial improvements in OS and
RFS following induction chemotherapy
+/- consolidation (non-HCT candidates)
300 mg orally daily for 14 d of 28-d
treatment cycles (QUAZAR study)Oral
azacitidine17,18
Epigenetic
modification
(novel oral
formulation
of HMA)
q Preliminary data from the ongoing phase 3 SIERRA
trial confirm the feasibility of targeted conditioning with
Iomab-B with near-universal and rapid engraftment of
older patients with active AML and high BM blast burden
q No nonrelapse mortality reported in the Iomab-B arm;
select nonhematologic AEs included stomatitis,
malnutrition, and epistaxis, among others
q In phase 3 testing, most common grade 3/4 AEs
included neutropenia, thrombocytopenia, and anemia